TY - JOUR
T1 - Association between systemic inflammation and obstructive sleep apnea in men with or at risk for HIV infection
AU - Brigham, Emily P.
AU - Patil, Susheel P.
AU - Jacobson, Lisa P.
AU - Margolick, Joseph B.
AU - Godfrey, Rebecca
AU - Johnson, Jacquett
AU - Johnson-Hill, Lisette M.
AU - Reynolds, Sandra
AU - Schwartz, Alan R.
AU - Smith, Philip L.
AU - Brown, Todd T.
N1 - Publisher Copyright:
©2014 International Medical Press
PY - 2014
Y1 - 2014
N2 - Background: We sought to determine whether markers of systemic inflammation are associated with the presence of moderate/severe obstructive sleep apnea (OSA) and whether this association differs based on HIV and HIV treatment status. Methods: HIV-uninfected men (HIV-; n=60), HIV-infected men receiving HAART (HIV+/HAART; n=58) and HIV-infected men not receiving HAART (HIV+/no HAART; n=41) underwent polysomnograpy and measurement of plasma levels of tumour necrosis factor (TNF)-α, soluble TNF-α receptors I and II (sTNFRI and sTNFRII) and interleukin (IL)-6. The relationship between moderate/severe OSA (respiratory disturbance index ≥15 apnea/hypopnea events/h) and inflammatory markers was assessed with multivariable regression models. Results: Compared with the HIV- men, HIV+/HAART men and HIV+/no HAART men had higher levels of TNF-α, sTNFRI and sTNFRII, independent of age, race, smoking status, obstructive lung disease (OLD) and body mass index (BMI). Moderate/severe OSA was present in 48% of the sample (HIV- 57%; HIV+/HAART 41%; HIV+/no HAART 44%). Among the HIV+/no HAART men, but not in the other groups, TNF-α, sTNFRII and IL-6 levels were higher in those with moderate/severe OSA compared to men with no/mild OSA after adjustment for age, race, smoking status, OLD and BMI. Within this group, the association of high TNF-α concentrations with moderate/severe OSA was also independent of CD4+ T-cell count and plasma HIV RNA concentration. Conclusions: Compared with HIV+/HAART men and HIV-men, markers of systemic inflammation were higher in HIV+/no HAART men. In these men, TNF-α was significantly related to OSA, independent of HIV-related covariates.
AB - Background: We sought to determine whether markers of systemic inflammation are associated with the presence of moderate/severe obstructive sleep apnea (OSA) and whether this association differs based on HIV and HIV treatment status. Methods: HIV-uninfected men (HIV-; n=60), HIV-infected men receiving HAART (HIV+/HAART; n=58) and HIV-infected men not receiving HAART (HIV+/no HAART; n=41) underwent polysomnograpy and measurement of plasma levels of tumour necrosis factor (TNF)-α, soluble TNF-α receptors I and II (sTNFRI and sTNFRII) and interleukin (IL)-6. The relationship between moderate/severe OSA (respiratory disturbance index ≥15 apnea/hypopnea events/h) and inflammatory markers was assessed with multivariable regression models. Results: Compared with the HIV- men, HIV+/HAART men and HIV+/no HAART men had higher levels of TNF-α, sTNFRI and sTNFRII, independent of age, race, smoking status, obstructive lung disease (OLD) and body mass index (BMI). Moderate/severe OSA was present in 48% of the sample (HIV- 57%; HIV+/HAART 41%; HIV+/no HAART 44%). Among the HIV+/no HAART men, but not in the other groups, TNF-α, sTNFRII and IL-6 levels were higher in those with moderate/severe OSA compared to men with no/mild OSA after adjustment for age, race, smoking status, OLD and BMI. Within this group, the association of high TNF-α concentrations with moderate/severe OSA was also independent of CD4+ T-cell count and plasma HIV RNA concentration. Conclusions: Compared with HIV+/HAART men and HIV-men, markers of systemic inflammation were higher in HIV+/no HAART men. In these men, TNF-α was significantly related to OSA, independent of HIV-related covariates.
UR - http://www.scopus.com/inward/record.url?scp=84921055304&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84921055304&partnerID=8YFLogxK
U2 - 10.3851/IMP2745
DO - 10.3851/IMP2745
M3 - Article
C2 - 24518040
AN - SCOPUS:84921055304
SN - 1359-6535
VL - 19
SP - 725
EP - 733
JO - Antiviral therapy
JF - Antiviral therapy
IS - 8
ER -